25 18 NEUROSPECTRUM LIMITED 13242053 false 2024-04-01 2025-03-31 2025-03-31 The principal activity of the company is that of clinical services. Digita Accounts Production Advanced 6.30.9574.0 true 13242053 2024-04-01 2025-03-31 13242053 2025-03-31 13242053 bus:OrdinaryShareClass1 bus:CumulativeShares 2025-03-31 13242053 core:CurrentFinancialInstruments 2025-03-31 13242053 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 13242053 core:OfficeEquipment 2025-03-31 13242053 bus:SmallEntities 2024-04-01 2025-03-31 13242053 bus:AuditExemptWithAccountantsReport 2024-04-01 2025-03-31 13242053 bus:FilletedAccounts 2024-04-01 2025-03-31 13242053 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 13242053 bus:RegisteredOffice 2024-04-01 2025-03-31 13242053 bus:Director1 2024-04-01 2025-03-31 13242053 bus:Director2 2024-04-01 2025-03-31 13242053 bus:OrdinaryShareClass1 bus:CumulativeShares 2024-04-01 2025-03-31 13242053 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 13242053 bus:Agent1 2024-04-01 2025-03-31 13242053 core:OfficeEquipment 2024-04-01 2025-03-31 13242053 countries:EnglandWales 2024-04-01 2025-03-31 13242053 2024-03-31 13242053 core:OfficeEquipment 2024-03-31 13242053 2023-04-01 2024-03-31 13242053 2024-03-31 13242053 bus:OrdinaryShareClass1 bus:CumulativeShares 2024-03-31 13242053 core:CurrentFinancialInstruments 2024-03-31 13242053 core:CurrentFinancialInstruments core:WithinOneYear 2024-03-31 13242053 core:OfficeEquipment 2024-03-31 xbrli:pure iso4217:GBP xbrli:shares

Registration number: 13242053

NEUROSPECTRUM LIMITED

Unaudited Filleted Financial Statements

for the Year Ended 31 March 2025

 

NEUROSPECTRUM LIMITED

Contents

Company Information

1

Balance Sheet

2

Notes to the Unaudited Financial Statements

3 to 7

 

NEUROSPECTRUM LIMITED

Company Information

Directors

J Hutchinson

P S Howie

Registered office

The Specialist Neurodevelopmental Clinic
25 Lansdowne Terrace
Gosforth
Newcastle Upon Tyne
NE3 1H

Accountants

K&S Professionals Limited
Chartered Certified Accountants41 Rivington Crescent
Mill Hill
London
NW7 2LF

 

NEUROSPECTRUM LIMITED

(Registration number: 13242053)
Balance Sheet as at 31 March 2025

Note

2025
£

2024
£

Fixed assets

 

Tangible assets

4

15,634

16,205

Current assets

 

Debtors

5

136,793

-

Cash at bank and in hand

 

556,783

308,989

 

693,576

308,989

Creditors: Amounts falling due within one year

6

(233,201)

(84,733)

Net current assets

 

460,375

224,256

Net assets

 

476,009

240,461

Capital and reserves

 

Called up share capital

7

100

100

Retained earnings

475,909

240,361

Shareholders' funds

 

476,009

240,461

For the financial year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 21 December 2025 and signed on its behalf by:
 

.........................................
J Hutchinson
Director

   
     
 

NEUROSPECTRUM LIMITED

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
The Specialist Neurodevelopmental Clinic
25 Lansdowne Terrace
Gosforth
Newcastle Upon Tyne
NE3 1H

These financial statements were authorised for issue by the Board on 21 December 2025.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

 

NEUROSPECTRUM LIMITED

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Office Equipment

25% Straight line method

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

 

NEUROSPECTRUM LIMITED

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 25 (2024 - 18).

 

NEUROSPECTRUM LIMITED

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

4

Tangible assets

Office equipment
£

Total
£

Cost or valuation

At 1 April 2024

28,828

28,828

Additions

11,278

11,278

At 31 March 2025

40,106

40,106

Depreciation

At 1 April 2024

12,623

12,623

Charge for the year

11,849

11,849

At 31 March 2025

24,472

24,472

Carrying amount

At 31 March 2025

15,634

15,634

At 31 March 2024

16,205

16,205

5

Debtors

Current

Note

2025
£

2024
£

Amounts owed by related parties

136,793

-

   

136,793

-

6

Creditors

Creditors: amounts falling due within one year

2025
£

2024
£

Due within one year

Taxation and social security

107,890

52,944

Accruals and deferred income

123,951

11,938

Other creditors

1,360

19,851

233,201

84,733

 

NEUROSPECTRUM LIMITED

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

7

Share capital

Allotted, called up and fully paid shares

2025

2024

No.

£

No.

£

Ordinary of £1 each

100

100

100

100